Physician profile
Joseph Riggi
NPI 1265436638
$3,041.88
in general payments reported to CMS, 2019-2025
29 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.02 · 2020: $376 · 2021: $140 · 2022: $229 · 2023: $301 · 2024: $882 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,281.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $531.22 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $396.49 | 2020-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals Lp | $337.78 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $307.33 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $265.55 | 2022-2025 | Vraylar |
| Amgen INC. | $193.51 | 2024-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $103.00 | 2020-2023 | |
| Abbott Laboratories | $89.63 | 2022-2024 | Freestyle Libre 3 |
| Antares Pharma, INC. | $83.87 | 2024-2025 | Xyosted |
| Sanofi-Aventis U.S. LLC | $67.39 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.13 | 2022-2025 | Jardiance |
| Glaxosmithkline, LLC. | $57.03 | 2020-2021 | |
| Exact Sciences Corporation | $55.75 | 2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $54.62 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $51.72 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $41.86 | 2022 | |
| Optos, INC. | $40.28 | 2020 | |
| Amarin Pharma, INC. | $39.75 | 2020 | |
| Acella Pharmaceuticals, LLC | $36.22 | 2024-2025 | NP Thyroid 60 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.16 | 2025 | Caplyta |
| Baxter Healthcare | $33.52 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Kowa Pharmaceuticals America, INC. | $28.17 | 2023 | Livalo, Seglentis |
| Dexcom, INC. | $22.92 | 2024 | Dexcom G6 Transmitter |
| Smith+Nephew, INC. | $22.18 | 2024 | Grafix Pl, Stravix Pl, Oasis |
| Halozyme INC | $21.64 | 2023 | |
| Novartis Pharmaceuticals Corporation | $21.17 | 2023 | |
| Convatec INC. | $16.51 | 2025 | |
| Pacira Therapeutics, INC. | $16.02 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.46 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Riggi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.